Innoviva receives FDA approval for HABP/VABP therapy
Co-packaged with sulbactam and durlobactam injections, XACDURO is said to be the first pathogen-targeted therapy addressing Acinetobacter, including resistant strains. It is intended for use in patients aged
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.